TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35389028

Group type: COMPARATOR
Intervention: Triple combination cream alone (control group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Triple combination cream + microneedling
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Triple combination cream + tranexamic acid (TA 250 mg twice daily)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Triple combination cream + microneedling + tranexamic acid
Number of subjects: 64
Study: 35944871

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 33675935

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 42
Study: 32854681

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) during surgery with preconditioning before aortic cross clamping (Arm 1)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Surgery without preconditioning before aortic cross clamping (Arm 2)
Number of subjects: 110
Study: 34889723

Group type: EXPERIMENTAL
Intervention: Envisia Genomic Classifier
Number of subjects: 11
Study: 36092537

Group type: EXPERIMENTAL
Intervention: Low-volume split-dose regimen two (1.5L PEG after dinner, 0.75L PEG 4 hours before colonoscopy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Low-volume split-dose regimen one (0.75L PEG after dinner, 1.5L PEG 4 hours before colonoscopy)
Number of subjects: 120
Study: 34272327

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 33190943

Group type: EXPERIMENTAL
Intervention: Contrast enhancement based adaptive denoising technique for speckle elimination and RPE layer extraction.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Statistical approach for AMD/normal classification.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified RPE detection algorithm.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Baseline estimation algorithm using randomization and polynomial fitting.
Number of subjects: 30
Study: 32894785

Group type: EXPERIMENTAL
Intervention: Siltuximab (anti-IL-6 therapy)
Number of subjects: 79
Study: 36396412

Group type: EXPERIMENTAL
Intervention: Reading 1 book a day (Group B)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reading 1 book a day and watching an infant brain development video (Group C)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Always reading 7 books per week
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Instructing parents to read daily
Number of subjects: 52

Group type: COMPARATOR
Intervention: No instructions (Group A)
Number of subjects: 52
Study: 33626485

Group type: EXPERIMENTAL
Intervention: Music-based interventions (live or recorded music)
Number of subjects: 8
Study: 32777163

Group type: EXPERIMENTAL
Intervention: Critical temperature (Tcrit) and initial response (m1) from segmented models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual scoring (stay-green) and chlorophyll fluorescence (ɸPSII) approaches
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daytime respiration
Number of subjects: 0
Study: 34100691

Group type: EXPERIMENTAL
Intervention: Hydrokinesiotherapy in a bucket for 10 minutes
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (CG) - only had the diaper changed
Number of subjects: 34
Study: 33047176

Group type: EXPERIMENTAL
Intervention: PQ repair
Number of subjects: 80

Group type: COMPARATOR
Intervention: No repair
Number of subjects: 80
Study: 35960896

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy (GCP: gefitinib 250 mg orally once daily combined with carboplatin plus pemetrexed in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gefitinib (250 mg orally, once daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gefitinib plus chemotherapy (GCP)
Number of subjects: 0
Study: 33793273

Group type: EXPERIMENTAL
Intervention: Individual-oriented relationship education (PREP's Within My Reach curriculum)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: All enrolled parents (treatment and control)
Number of subjects: 322
Study: 32826010

Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique (MET)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mechanical Diagnosis and Therapy (MDT)
Number of subjects: 20
Study: 36075775

Group type: EXPERIMENTAL
Intervention: Rude response condition
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Psychological safety
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Across conditions
Number of subjects: 125
Study: 34890350

Group type: EXPERIMENTAL
Intervention: TrendMD promotion for 6 months
Number of subjects: 3200

Group type: COMPARATOR
Intervention: Control group (no promotion)
Number of subjects: 3200
Study: 36271176

Group type: EXPERIMENTAL
Intervention: RT + TACE
Number of subjects: 120

Group type: COMPARATOR
Intervention: TACE + RT
Number of subjects: 120
Study: 32811749

Group type: EXPERIMENTAL
Intervention: Integrative medicine visits
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard medical visits
Number of subjects: 21
Study: 32786325

Group type: EXPERIMENTAL
Intervention: Sparse measurements of library molecules using a machine learning algorithm to predict molecular function.
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Amino acid sequences that bind weakly to a target.
Number of subjects: 1012
Study: 35522848

Group type: EXPERIMENTAL
Intervention: Implicit racial bias measured using the child‐race implicit association test (IAT)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Strong pro‐White implicit bias
Number of subjects: 119

Group type: COMPARATOR
Intervention: Clinical decision making (opioid recommendations, management decisions, patient perceptions)
Number of subjects: 119
Study: 32216594

Group type: EXPERIMENTAL
Intervention: Orange juice (pH = 3.5) with Phenobarbital (2.5 mg/kg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mineral water (neutral pH) with Phenobarbital (2.5 mg/kg)
Number of subjects: 40
Study: 33217626

Group type: EXPERIMENTAL
Intervention: ASP-F≥25 mm (n=6; follicle aspiration 25-29 mm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ASP-F≥30 mm (n=6; follicle aspiration 30-34 mm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ASP-F≥35 mm (n=6; follicle aspiration 35-40 mm)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ASP-F≥40 mm (n=6; follicle aspiration ≥40 mm)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (n=5; spontaneous ovulation or no follicle aspiration)
Number of subjects: 15
Study: 32569700

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 10142

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10142
Study: 34563243

Group type: EXPERIMENTAL
Intervention: Adalimumab biosimilar PF-06410293 (ADL-PF)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Week 26 switch from reference adalimumab (ADL-EU) to ADL-PF
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Week 52 switch from ADL-EU to ADL-PF
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Week 26 switch from ADL-EU to ADL-PF
Number of subjects: 507
Study: 33326877

Group type: EXPERIMENTAL
Intervention: EMR‐CDS
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: EMR‐CDS + BHI‐CCM
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 35
Study: 32162727

Group type: EXPERIMENTAL
Intervention: Pelvic floor and mobility exercises led by village paramedics
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Further 6-month exercise intervention led by village paramedics
Number of subjects: 466

Group type: COMPARATOR
Intervention: Physiotherapy preceptors in the CRT
Number of subjects: 466
Study: 35458200

Group type: EXPERIMENTAL
Intervention: High-dose kawakawa tea (4 g/250 mL water)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 30
Study: 33144226

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) interscalene nerve block (ISNB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard bupivacaine ISNB (control)
Number of subjects: 100
Study: 32533189

Group type: EXPERIMENTAL
Intervention: Genetically elevated SHBG
Number of subjects: 334977
Study: 35007479

Group type: EXPERIMENTAL
Intervention: Cognitive Developmental Hypnotherapy (CDH)
Number of subjects: 40
Study: 34882729

Group type: EXPERIMENTAL
Intervention: Medicine ball throws protocol (3 sets of 6 repetitions using a 2 kg ball, throwing at maximal speed)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Resistance training protocol (3 sets of 6 repetitions at 75% one-repetition maximum, lifting at maximal speed)
Number of subjects: 10
Study: 33052500

Group type: EXPERIMENTAL
Intervention: Strong fixation preference (SFP) group (Group 1)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Alternating fixation group (Group 2)
Number of subjects: 77
Study: 32557478

Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion (HMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine perfusion (MP)
Number of subjects: 0
Study: 34300161

Group type: EXPERIMENTAL
Intervention: Group CA‐CBT (16 sessions)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Individual CA‐CBT (8 sessions)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 64
Study: 33775611

Group type: EXPERIMENTAL
Intervention: Selective-suturing or sutureless technique (suRAPN)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard RAPN (stRAPN)
Number of subjects: 92
Study: 33840928

Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope guided intubation using Frova introducer
Number of subjects: 140

Group type: COMPARATOR
Intervention: C-MAC video laryngoscope guided intubation without Frova introducer
Number of subjects: 140
Study: 36214737

Group type: EXPERIMENTAL
Intervention: Revised Care Plan Checklist for Evidence of Person-Centered Care Approaches for BPSD
Number of subjects: 103
Study: 32290681

Group type: EXPERIMENTAL
Intervention: Positive coping and perceived stress interventions
Number of subjects: 0
Study: 33766422

Group type: COMPARATOR
Intervention: Prevenar13™ (PCV13) (_PPP)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Synflorix™ (PHiD-CV10) (_SSS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Mixed primary series of PHiD-CV10 and PCV13 (SSSP)
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Ear discharge swabs (n = 108)
Number of subjects: 425
Study: 34139404

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (12-week duration)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 53
Study: 34360184

Group type: EXPERIMENTAL
Intervention: G% (1RM test group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GPE (RPE group)
Number of subjects: 25
Study: 35945770

Group type: EXPERIMENTAL
Intervention: Supervised physical therapy exercise program plus 20 minutes PBMT (650 nm, 5 mW, 1 cm², 6 Joules, 3 sessions/week for 8 weeks) plus traditional medical treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: PBMT (same protocol as Group A, 3 sessions/week for 8 weeks) plus traditional medical treatment
Number of subjects: 40
Study: 34454404

Group type: EXPERIMENTAL
Intervention: Postgraduate dermatology training
Number of subjects: 456

Group type: COMPARATOR
Intervention: General community pharmacists
Number of subjects: 456

Group type: COMPARATOR
Intervention: Community pharmacists
Number of subjects: 456
Study: 32445052

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 16
Study: 35179523

Group type: EXPERIMENTAL
Intervention: 3D limb scanning
Number of subjects: 30

Group type: COMPARATOR
Intervention: Physical measurements
Number of subjects: 30
Study: 33978833

Group type: EXPERIMENTAL
Intervention: Grape juice (condition sugar)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Water (condition water)
Number of subjects: 122
Study: 32202830

Group type: EXPERIMENTAL
Intervention: Integrated Care Program (ICP)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 153
Study: 35276223

Group type: EXPERIMENTAL
Intervention: Adalimumab with methotrexate (ADL-MTX)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Adalimumab monotherapy (ADL)
Number of subjects: 61
Study: 33248882

Group type: EXPERIMENTAL
Intervention: Teaching intervention delivered by CMR physicians
Number of subjects: 25
Study: 34428930

Group type: EXPERIMENTAL
Intervention: Sonothrombolysis (ultrasound-enhanced thrombolysis)
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Intravenous thrombolysis alone
Number of subjects: 1102

Group type: EXPERIMENTAL
Intervention: Sonothrombolysis
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Control (Intravenous thrombolysis alone)
Number of subjects: 1102
Study: 33305723

Group type: EXPERIMENTAL
Intervention: Posaconazole injection 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Posaconazole injection 200 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Posaconazole injection 300 mg
Number of subjects: 36
Study: 33723616

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training combined with neuromuscular electrical stimulation of the paraspinal muscles for 12 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation for 12 weeks
Number of subjects: 96
Study: 33115536

Group type: EXPERIMENTAL
Intervention: Numeric expressions
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Graphical presentations
Number of subjects: 225

Group type: COMPARATOR
Intervention: Verbal expressions
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: 'Don't know' responses
Number of subjects: 225
Study: 36098936

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 930

Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 930

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study: 33629803

Group type: EXPERIMENTAL
Intervention: Autoregulated heavy slow resistance training (HSRT) combined with extracorporeal shockwave therapy (ESWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autoregulated heavy slow resistance training (HSRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 0
Study: 32818281

Group type: EXPERIMENTAL
Intervention: Transtendon repair technique
Number of subjects: 64
Study: 36192126

Group type: EXPERIMENTAL
Intervention: Short-course outpatient antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-course outpatient antibiotic therapy
Number of subjects: 0
Study: 34014695

Group type: EXPERIMENTAL
Intervention: Tele.TAnDem (telephone-based cognitive-behavioral therapy) consisting of 12 sessions over 6 months
Number of subjects: 51

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 51
Study: 34185333

Group type: EXPERIMENTAL
Intervention: Leukocyte-reduced platelet-rich plasma (PRP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 11
Study: 33845211

Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg every 2 weeks
Number of subjects: 792

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1+ ≥50% subgroup
Number of subjects: 792

Group type: COMPARATOR
Intervention: Docetaxel in PD-L1+ ≥50% subgroup
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Avelumab in PD-L1+ ≥80% subgroup
Number of subjects: 792

Group type: COMPARATOR
Intervention: Docetaxel in PD-L1+ ≥80% subgroup
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Avelumab
Number of subjects: 792
Study: 35856817

Group type: EXPERIMENTAL
Intervention: Oral Methotrexate 7.5 mg weekly for a maximum of 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral Mini Pulse Betamethasone 3 mg weekly for a maximum of 12 weeks
Number of subjects: 40
Study: 34251927

Group type: EXPERIMENTAL
Intervention: Risk Awareness and Perception Training (RAPT) program
Number of subjects: 5036

Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 5036
Study: 35921241

Group type: EXPERIMENTAL
Intervention: Structured exercise programme consisting of close kinetic chain (CKC) exercises 2 days a week for 12 weeks, in addition to prophylactic treatment.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Conventional Treatment Group (CTG) received exercise training as described in the published literature.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control Group (CG) continued to receive prophylactic treatment during the study period.
Number of subjects: 21
Study: 32126964

Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control
Number of subjects: 160
Study: 36404406

Group type: EXPERIMENTAL
Intervention: HM3 LVAD
Number of subjects: 918

Group type: COMPARATOR
Intervention: HMII LVAD
Number of subjects: 918

Group type: EXPERIMENTAL
Intervention: Combined HM3 group
Number of subjects: 918
Study: 34444739

Group type: EXPERIMENTAL
Intervention: Fine stoneground flour bread
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Coarse stoneground flour bread
Number of subjects: 23
Study: 32266380

Group type: COMPARATOR
Intervention: 100 mg of aspirin once daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin twice daily
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin thrice daily
Number of subjects: 245
Study: 35405656

Group type: EXPERIMENTAL
Intervention: Financial incentives ($10 incentive when tested for HIV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft commitment (behavioral nudge)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information only
Number of subjects: 0
Study: 34415356

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 3523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3523
Study: 32881764

Group type: EXPERIMENTAL
Intervention: Heading (n = 22)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Kicking-control (n = 17)
Number of subjects: 39
Study: 35665724

Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment (IMKT) + Non-resistance manual therapy (NRT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Integrative Korean medicine treatment (IMKT)
Number of subjects: 120
Study: 32279591

Group type: EXPERIMENTAL
Intervention: Variable voltage electronic cigarette batteries
Number of subjects: 0
Study: 34126263

Group type: EXPERIMENTAL
Intervention: Song-based, video-guided intervention for independent application of sunscreen during a 10-day intervention period.
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Teacher and student perceptions of intervention value and utility were evaluated during the intervention period.
Number of subjects: 96
Study: 33065035

Group type: EXPERIMENTAL
Intervention: QVLP vaccine (30 μg haemagglutinin per strain)
Number of subjects: 10160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10160

Group type: COMPARATOR
Intervention: Quadrivalent inactivated vaccine (QIV; 15 μg haemagglutinin per strain)
Number of subjects: 10160
Study: 36182540

Group type: EXPERIMENTAL
Intervention: Nurse-led delirium-prevention protocol
Number of subjects: 2566

Group type: COMPARATOR
Intervention: Preintervention (baseline) period
Number of subjects: 2566
Study: 34432727

Group type: EXPERIMENTAL
Intervention: Case management program for 8 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine clinical care (control)
Number of subjects: 62
Study: 33235017

Group type: EXPERIMENTAL
Intervention: Experimental running program (EXP, n = 22)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Traditional military running program (TRA, n = 28)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Experimental running program (EXP) after crossover
Number of subjects: 50
Study: 35537105

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy as per protocol
Number of subjects: 3176
Study: 34032510

Group type: EXPERIMENTAL
Intervention: van Leeuwen model
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Mehralivand model
Number of subjects: 385

Group type: COMPARATOR
Intervention: PI-RADS plus PSAd strategy
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: MRIERSPC, Radtke, Mehralivand models (without prior recalibration)
Number of subjects: 385
Study: 35712008

Group type: EXPERIMENTAL
Intervention: Psychological intervention‐assisted comfort care based on the PERMA model
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 100
Study: 34524157

Group type: EXPERIMENTAL
Intervention: Phenylephrine (50 μg)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Norepinephrine (4 μg)
Number of subjects: 86
Study: 32087175

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 174
Study: 36105122

Group type: COMPARATOR
Intervention: BCAA+FO supplement group (n=10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: BCAA group (n=10)
Number of subjects: 29

Group type: COMPARATOR
Intervention: BCAA+FO group (n=10)
Number of subjects: 29
Study: 33619708

Group type: EXPERIMENTAL
Intervention: Preoperative thoracic paravertebral block with 0.5% bupivacaine
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Postoperative oxycodone combined with nonopioid analgesics
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: α-amylase levels
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 70
Study: 32719129

Group type: EXPERIMENTAL
Intervention: Medicare bundled payment reform
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (areas without payment reform)
Number of subjects: 0
Study: 36301543

Group type: EXPERIMENTAL
Intervention: Lotus valve
Number of subjects: 912

Group type: COMPARATOR
Intervention: CoreValve/EvolutR
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 912